Development of Ligand-Transformed Alpha-Fetoprotein for Use Against Breast Cancer in Humans.
Abstract
Human alpha-fetoprotein (hAFP) upon incubation with sex steroid hormones is chemically converted into an inhibitor of estrogen-dependent breast cancer growth. This document describes the progress which was made during the first year of a research grant which was designed to develop the active form of hAFP as a treatment for breast cancer and establish markers which both predict and monitor breast cancer responsiveness to this form of AFP.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1995
- Accession Number
- ADA299826
Entities
People
- James A. Bennett
Organizations
- Albany Medical College